IL2 and immune system disorder: As cancer is a disease of aging and associated immune dysfunction, our finding here showing an accelerated loss of pSTAT1 activation in response to IL-2 in the melanoma patients may relate to this differential loss of NK activity in the normal human population making some individuals more prone to cancer and/or less able to control cancer progression through immune-mediated mechanisms.